According to a report from Jota on January 15th, the Brazilian National Health Surveillance Agency (Anvisa) plans to allocate approximately 70,000 reais (about $10,000) to dispatch two directors and two staff members to visit the production facilities of British American Tobacco (BAT) and pharmaceutical company AstraZeneca next week. The visits are expected to take place between January 28th and 31st. The mission was approved last week, but specific objectives have not yet been determined, and the visit times for each facility have not been disclosed.
The visit took place at a time when the pressure was mounting for the introduction of e-cigarettes in the country. This issue is currently being discussed in Congress and has previously been debated within Anvisa. In April 2024, the board of Anvisa decided to maintain the ban on e-cigarettes based on the principle of prevention. They believed that these devices should only be produced and sold if safety evidence is provided, but as of now, there is no research to support this.
The task has raised concerns among internal Anvisa employees, who state that there are currently no discussions related to tobacco taking place. JOTA interviewed Anvisa's board members, who stated that this type of visit is a routine practice and does not require a specific reason. Even if there are no specific discussions or regulatory agenda items, inspections of regulated industry production sites will still take place. In response to inquiries from the public, Anvisa did not provide specific details about the itinerary of the visit, only stating in a release that there are no plans to reintroduce e-cigarette-related topics to Anvisa's regulatory agenda at this time.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
